Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab

Chronic lymphocytic leukaemia (CLL) is one of the most common haematological malignancies worldwide, with an increasing prevalence in the elderly population. Obinutuzumab is a type II anti-CD20 monoclonal antibody which showed superiority over rituximab in combination chemotherapy with chlorambucil...

Descripción completa

Detalles Bibliográficos
Autores principales: Mustafa, Mohamad, Mohamed, Mohamed B, Hayat, Amjad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346921/
https://www.ncbi.nlm.nih.gov/pubmed/30755907
http://dx.doi.org/10.12890/2016_000516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346921/
https://www.ncbi.nlm.nih.gov/pubmed/30755907
http://dx.doi.org/10.12890/2016_000516

Ejemplares similares